Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
暂无分享,去创建一个
P. Cony-Makhoul | L. Knoops | V. Ugo | E. Lippert | K. Laribi | J. Rey | P. Hutin | L. Roy | E. Gyan | C. Dosquet | J. Demory | B. Dupriez | J. Kiladjian | A. Chauveau | J. Ianotto | D. Ranta | L. Legros | B. de Renzis | O. Benbrahim | M. Malou | F. Boyer-Perrard